{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T01:26:56Z","timestamp":1648862816205},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2008,3,29]],"date-time":"2008-03-29T00:00:00Z","timestamp":1206748800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Cardio Med"],"published-print":{"date-parts":[[2008,4]]},"DOI":"10.1007\/s11936-008-0016-y","type":"journal-article","created":{"date-parts":[[2008,3,28]],"date-time":"2008-03-28T14:56:43Z","timestamp":1206716203000},"page":"146-155","source":"Crossref","is-referenced-by-count":3,"title":["Raynaud\u2019s phenomenon"],"prefix":"10.1007","volume":"10","author":[{"given":"Ariane","family":"Herrick","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,3,29]]},"reference":[{"key":"16_CR1","volume-title":"Local Asphyxia and Symmetrical Gangrene of the Extremities 1862. New Researches on the Nature and Treatment of Local Asphyxia of the Extremities 1874","author":"M. Raynaud","year":"1888","unstructured":"Raynaud M: Local Asphyxia and Symmetrical Gangrene of the Extremities 1862. New Researches on the Nature and Treatment of Local Asphyxia of the Extremities 1874. Translated by Barlow T. London: New Sydenham Society; 1888."},{"key":"16_CR2","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJMcp013013","volume":"347","author":"F.M. Wigley","year":"2002","unstructured":"Wigley FM: Raynaud\u2019s phenomenon. N Eng J Med 2002, 347:1001\u20131008.","journal-title":"N Eng J Med"},{"key":"16_CR3","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1093\/rheumatology\/keh552","volume":"44","author":"A.L. Herrick","year":"2005","unstructured":"Herrick AL: Pathogenesis of Raynaud\u2019s phenomenon. Rheumatology 2005, 44:587\u2013596.","journal-title":"Rheumatology"},{"key":"16_CR4","first-page":"321","volume":"338","author":"A.P. Fishman","year":"1998","unstructured":"Fishman AP: Pulmonary hypertension-beyond vasodilator therapy. N Eng J Med 1998, 338:321\u2013322.","journal-title":"N Eng J Med"},{"key":"16_CR5","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1053\/hj.1998.v135.86971","volume":"135","author":"S.G. Chrysant","year":"1998","unstructured":"Chrysant SG: Vascular remodeling: the role of angiotensin-converting enzyme inhibitors. Am Heart J 1998, 135:S21\u2013S30.","journal-title":"Am Heart J"},{"key":"16_CR6","doi-asserted-by":"crossref","first-page":"312","DOI":"10.3181\/00379727-221-44414","volume":"221","author":"M. Kirchengast","year":"1999","unstructured":"Kirchengast M, M\u00fcnter K: Endothelin-1 and endothelin receptor antagonists in cardiovascular remodeling. Proc Soc Exp Biol Med 1999, 221:312\u2013325.","journal-title":"Proc Soc Exp Biol Med"},{"key":"16_CR7","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/0049-0172(75)90017-7","volume":"4","author":"P.M. Campbell","year":"1975","unstructured":"Campbell PM, LeRoy EC: Pathogenesis of systemic sclerosis: a vascular hypothesis. Sem Arthritis Rheum 1975, 4:351\u2013368.","journal-title":"Sem Arthritis Rheum"},{"key":"16_CR8","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/00005792-198011000-00001","volume":"59","author":"G.P. Rodnan","year":"1980","unstructured":"Rodnan GP, Myerowitz RL, Justh GO: Morphological changes in the digital arteries of patients with progressive systemic sclerosis (scleroderma) and Raynaud phenomenon. Medicine 1980, 59:393\u2013408.","journal-title":"Medicine"},{"key":"16_CR9","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1002\/art.10685","volume":"46","author":"B.J. Harrison","year":"2002","unstructured":"Harrison BJ, Silman AJ, Hider SL, Herrick AL: Cigarette smoking: a significant risk factor for digital vascular disease in patients with systemic sclerosis. Arthritis Rheum 2002, 46:3312\u20133316.","journal-title":"Arthritis Rheum"},{"key":"16_CR10","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1001\/archinte.160.8.1101","volume":"160","author":"Raynaud\u2019s Treatment Study Investigators","year":"2000","unstructured":"Raynaud\u2019s Treatment Study Investigators: Comparison of sustained-release nifedipine and temperature biofeedback for treatment of primary Raynaud phenomenon. Results from a randomized clinical trial with 1-year follow-up. Arch Intern Med 2000, 160:1101\u20131108.","journal-title":"Arch Intern Med"},{"key":"16_CR11","doi-asserted-by":"crossref","first-page":"610","DOI":"10.7326\/0003-4819-96-5-610","volume":"96","author":"M.B. Kahaleh","year":"1982","unstructured":"Kahaleh MB, Osborn I, LeRoy EC: Elevated levels of circulating platelet aggregates and beta-thromboglobulin in scleroderma. Ann Int Med 1982, 96:610\u2013613.","journal-title":"Ann Int Med"},{"key":"16_CR12","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1002\/art.10486","volume":"46","author":"P.A. Merkel","year":"2002","unstructured":"Merkel PA, Herlyn K, Martin RW, et al.: Measuring disease activity and functional status in patients with scleroderma and Raynaud\u2019s phenomenon. Arthritis Rheum 2002, 46:2410\u20132420.","journal-title":"Arthritis Rheum"},{"key":"16_CR13","doi-asserted-by":"crossref","first-page":"3985","DOI":"10.1002\/art.20676","volume":"50","author":"J.H. Korn","year":"2004","unstructured":"Korn JH, Mayes M, Matucci Cerinic M, et al.: for the RAPIDS-1 Study Group: Digital ulcers in systemic sclerosis. Prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 2004, 50:3985\u20133993.","journal-title":"Arthritis Rheum"},{"key":"16_CR14","doi-asserted-by":"crossref","first-page":"3837","DOI":"10.1002\/art.22965","volume":"56","author":"A.E. Gliddon","year":"2007","unstructured":"Gliddon AE, Dor\u2019e CJ, Black CM, et al.: Prevention of vascular damage in scleroderma and autoimmune Raynaud\u2019s phenomenon: a randomised controlled trial of the ACE-inhibitor quinapril. Arthritis Rheum 2007, 56:3837\u20133846.","journal-title":"Arthritis Rheum"},{"key":"16_CR15","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/0002-9343(85)90402-4","volume":"78","author":"R. Malamet","year":"1985","unstructured":"Malamet R, Wise RA, Ettinger WH, Wigley FM: Nifedipine in the treatment of Raynaud\u2019s phenomenon. Evidence for inhibition of platelet activation. Am J Med 1985, 78:602\u2013608.","journal-title":"Am J Med"},{"key":"16_CR16","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.amjmed.2003.11.022","volume":"116","author":"Y. Allanore","year":"2004","unstructured":"Allanore Y, Borderie D, Lemarechal H, et al.: Acute and sustained effects of dihydropyridine-type calcium channel antagonists on oxidative stress in systemic sclerosis. Am J Med 2004, 116:595\u2013600.","journal-title":"Am J Med"},{"key":"16_CR17","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/rheumatology\/keh390","volume":"44","author":"A.E. Thompson","year":"2005","unstructured":"Thompson AE, Pope JE: Calcium channel blockers for primary Raynaud\u2019s phenomenon: a meta-analysis. Rheumatology 2005, 44:145\u2013150.","journal-title":"Rheumatology"},{"key":"16_CR18","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1002\/1529-0131(200108)44:8<1841::AID-ART322>3.0.CO;2-8","volume":"44","author":"A.E. Thompson","year":"2001","unstructured":"Thompson AE, Shea B, Welch V, et al.: Calcium-channel blockers for Raynaud\u2019s phenomenon in systemic sclerosis. Arthritis Rheum 2001, 44:1841\u20131847.","journal-title":"Arthritis Rheum"},{"key":"16_CR19","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1002\/1529-0131(199912)42:12<2646::AID-ANR21>3.0.CO;2-T","volume":"42","author":"M. Dziadzio","year":"1999","unstructured":"Dziadzio M, Denton CP, Smith R, et al.: Losartan therapy for Raynaud\u2019s phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial. Arthritis Rheum 1999, 42:2646\u20132655.","journal-title":"Arthritis Rheum"},{"key":"16_CR20","doi-asserted-by":"crossref","unstructured":"Pope J, Fenlon D, Thompson A, et al.: Prazosin for Raynaud\u2019s phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev 1998, CD000956.","DOI":"10.1002\/14651858.CD000954"},{"key":"16_CR21","doi-asserted-by":"crossref","unstructured":"Pope J, Fenlon D, Thompson A, et al.: Iloprost and cisaprost for Raynaud\u2019s phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev 1998, CD000953.","DOI":"10.1002\/14651858.CD000953"},{"key":"16_CR22","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1002\/1529-0131(199804)41:4<670::AID-ART14>3.0.CO;2-I","volume":"41","author":"F.M. Wigley","year":"1998","unstructured":"Wigley FM, Korn JH, Csuka ME, et al.: Oral iloprost treatment in patients with Raynaud\u2019s phenomenon secondary to systemic sclerosis: a multi-center, placebo-controlled, double-blind study. Arthritis Rheum 1998, 41:670\u2013677.","journal-title":"Arthritis Rheum"},{"key":"16_CR23","first-page":"2173","volume":"26","author":"M. Vayssairat","year":"1999","unstructured":"Vayssairat M: Preventative effect of an oral prostacyclin analog, beroprost sodium, on digital necrosis in systemic sclerosis. French Microcirculation Society Multicentre Group for the Study of Vascular Acrosyndromes. J Rheumatol 1999, 26:2173\u20132178.","journal-title":"J Rheumatol"},{"key":"16_CR24","doi-asserted-by":"crossref","first-page":"199","DOI":"10.7326\/0003-4819-120-3-199402010-00004","volume":"120","author":"F.M. Wigley","year":"1994","unstructured":"Wigley FM, Wise RA, Seibold JR, et al.: Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, doubleblind study. Ann Intern Med 1994, 120:199\u2013206.","journal-title":"Ann Intern Med"},{"issue":"SupplII","key":"16_CR25","first-page":"90","volume":"65","author":"J.R. Seibold","year":"2006","unstructured":"Seibold JR, Matucci-Cerinic M, Denton CP, et al.: Bosentan reduces the number of new digital ulcers in patients with systemic sclerosis [abstract]. Ann Rheum Dis 2006, 65(Suppl II):90.","journal-title":"Ann Rheum Dis"},{"key":"16_CR26","doi-asserted-by":"crossref","unstructured":"Pope J, Fenlon D, Thompson A, et al.: Ketanserin for Raynaud\u2019s phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev 1998, CD000954.","DOI":"10.1002\/14651858.CD000954"},{"key":"16_CR27","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1093\/rheumatology\/40.9.1038","volume":"40","author":"B. Coleiro","year":"2001","unstructured":"Coleiro B, Marshall SE, Denton CP, et al.: Treatment of Raynaud\u2019s phenomenon with the selective serotonin reuptake inhibitor fluoxetine. Rheumatology 2001, 40:1038\u20131043.","journal-title":"Rheumatology"},{"key":"16_CR28","first-page":"269","volume":"25","author":"A.M. Yee","year":"1998","unstructured":"Yee AM, Hotchkiss RN, Paget SA: Adventitial stripping: adigit saving procedure in refractory Raynaud\u2019s phenomenon. J Rheumatol 1998, 25:269\u2013276.","journal-title":"J Rheumatol"},{"key":"16_CR29","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1053\/jhsu.1999.jhsu24a0173","volume":"24","author":"T.E. McCall","year":"1999","unstructured":"McCall TE, Petersen DP, Wong LB: The use of digital artery sympathectomy as a salvage procedure for severe ischemia of Raynaud\u2019s disease and phenomenon. J Hand Surg [Am] 1999, 24:173\u2013177.","journal-title":"J Hand Surg [Am]"},{"key":"16_CR30","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/micr.1013","volume":"21","author":"M.M. Tomaino","year":"2001","unstructured":"Tomaino MM, Goitz RJ, Medsger TA: Surgery for ischemic pain and Raynaud\u2019s phenomenon in scleroderma: a description of treatment protocol and evaluation of results. Microsurgery 2001, 21:75\u201379.","journal-title":"Microsurgery"},{"key":"16_CR31","first-page":"1788","volume":"30","author":"S.V. Kotsis","year":"2003","unstructured":"Kotsis SV, Chung KC: A systematic review of the outcomes of digital sympathectomy for treatment of chronic digital ischemia. J Rheumatol 2003, 30:1788\u20131792.","journal-title":"J Rheumatol"},{"key":"16_CR32","first-page":"102","volume":"29","author":"M.H. Taylor","year":"2002","unstructured":"Taylor MH, McFadden JA, Bolster MB, Silver RM: Ulnar artery involvement in systemic sclerosis (scleroderma). J Rheumatol 2002, 29:102\u2013106.","journal-title":"J Rheumatol"},{"key":"16_CR33","first-page":"39","volume":"27","author":"T. Klyscz","year":"1998","unstructured":"Klyscz T, Junger M, Meyer H, Rassner G: Improvement of acral circulation in a patient with systemic sclerosis with stellate blocks. Vasa 1998, 27:39\u201342.","journal-title":"Vasa"},{"key":"16_CR34","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1136\/ard.54.10.853","volume":"54","author":"D.J. Veale","year":"1995","unstructured":"Veale DJ, Collidge TA, Belch JJF: Increased prevalence of symptomatic macrovascular disease in systemic sclerosis. Ann Rheum Dis 1995, 54:853\u2013855.","journal-title":"Ann Rheum Dis"},{"key":"16_CR35","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1093\/rheumatology\/34.7.636","volume":"34","author":"L.S. Teh","year":"1995","unstructured":"Teh LS, Manning J, Moore T, et al.: Sustained-release transdermal glyceryl trinitrate patches as a treatment for primary and secondary Raynaud\u2019s phenomenon. Br J Rheumatol 1995, 34:636\u2013641.","journal-title":"Br J Rheumatol"},{"key":"16_CR36","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S0140-6736(05)64133-5","volume":"350","author":"F. Khan","year":"1997","unstructured":"Khan F, Greig IR, Newton DJ, et al.: Skin blood flow after transdermal S-nitrosothio-acetylglucose. Lancet 1997, 350:410\u2013411.","journal-title":"Lancet"},{"key":"16_CR37","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(99)04095-7","volume":"354","author":"A.T. Tucker","year":"1999","unstructured":"Tucker AT, Pearson RM, Cooke ED, Benjamin N: Effect of nitric-oxide-generating system on microcirculatory blood flow in skin in patients with severe Raynaud\u2019s syndrome: a randomised trial. Lancet 1999, 354:1670\u20131675.","journal-title":"Lancet"},{"key":"16_CR38","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1093\/rheumatology\/41.3.324","volume":"41","author":"M.E. Anderson","year":"2002","unstructured":"Anderson ME, Moore TL, Hollis S, et al.: Digital vascular response to topical glyceryl trinitrate, as measured by laser Doppler imaging, in primary Raynaud\u2019s phenomenon and systemic sclerosis. Rheumatology 2002, 41:324\u2013328.","journal-title":"Rheumatology"},{"issue":"Suppl","key":"16_CR39","first-page":"S824","volume":"56","author":"L. Chung","year":"2007","unstructured":"Chung L, Baron M, Collier D, et al.: A multi-center placebo-controlled \u201cin-life\u201d study of MQX-503 in patients with Raynaud\u2019s phenomenon [abstract]. Arthritis Rheum 2007, 56(Suppl):S824.","journal-title":"Arthritis Rheum"},{"key":"16_CR40","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1136\/ard.2003.015677","volume":"63","author":"C.R. Kumana","year":"2004","unstructured":"Kumana CR, Cheung GTY, Lau CS: Severe digital ischaemia treated with phosphodiesterase inhibitors. Ann Rheum Dis 2004, 63:1522\u20131524.","journal-title":"Ann Rheum Dis"},{"key":"16_CR41","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1161\/CIRCULATIONAHA.104.523324","volume":"112","author":"R. Fries","year":"2005","unstructured":"Fries R, Shariat K, von Wilmowsky H, Bohm M: Sildenafil in the treatment of Raynaud\u2019s phenomenon resistant to vasodilatory therapy. Circulation 2005, 112:2980\u20132985.","journal-title":"Circulation"},{"key":"16_CR42","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1136\/ard.2004.034488","volume":"64","author":"J. Gore","year":"2005","unstructured":"Gore J, Silver R: Oral sildenafil for the treatment of Raynaud\u2019s phenomenon and digital ulcers secondary to systemic sclerosis. Ann Rheum Dis 2005, 64:1387.","journal-title":"Ann Rheum Dis"},{"key":"16_CR43","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1001\/archinte.166.2.231","volume":"166","author":"E. Caglayan","year":"2006","unstructured":"Caglayan E, Huntegeburth M, Karasch T, et al.: Phosphodiesterase type 5 inhibition is a novel therapeutic option in Raynaud disease. Arch Int Med 2006, 166:231\u2013233.","journal-title":"Arch Int Med"},{"key":"16_CR44","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/j.amjcard.2003.08.013","volume":"92","author":"S. Rajagopalan","year":"2003","unstructured":"Rajagopalan S, Pfenninger D, Somers E, et al.: Effects of cilostazol in patients with Raynaud\u2019s syndrome. Am J Cardiol 2003, 92:1310\u20131315.","journal-title":"Am J Cardiol"},{"key":"16_CR45","first-page":"4","volume":"19","author":"A.L. Herrick","year":"2001","unstructured":"Herrick AL, Matucci Cerinic M: The emerging problem of oxidative stress and the role of antioxidants in systemic sclerosis. Clin Exp Rheumatol 2001, 19:4\u20138.","journal-title":"Clin Exp Rheumatol"},{"key":"16_CR46","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/rheumatology\/38.4.309","volume":"38","author":"C.P. Denton","year":"1999","unstructured":"Denton CP, Bunce TD, Dorado MB, et al.: Probucol improves symptoms and reduces lipoprotein oxidation susceptibility in patients with Raynaud\u2019s phenomenon. Rheumatology 1999, 38:309\u2013315.","journal-title":"Rheumatology"},{"key":"16_CR47","first-page":"349","volume":"18","author":"A.L. Herrick","year":"2000","unstructured":"Herrick AL, Hollis S, Schofield D, et al.: A double-blind placebo-controlled trial of antioxidant therapy in limited cutaneous systemic sclerosis. Clin Exp Rheumatol 2000, 18:349\u2013356.","journal-title":"Clin Exp Rheumatol"},{"key":"16_CR48","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/art.1780271009","volume":"27","author":"V.L. Beckett","year":"1984","unstructured":"Beckett VL, Conn DL, Fuster V, et al.: Trial of platelet-inhibiting drug in scleroderma. Arthritis Rheum 1984, 27:1137\u20131143.","journal-title":"Arthritis Rheum"},{"key":"16_CR49","doi-asserted-by":"crossref","first-page":"H1075","DOI":"10.1152\/ajpheart.2000.278.4.H1075","volume":"278","author":"M.A. Chotani","year":"2000","unstructured":"Chotani MA, Flavahan S, Mitra S, et al.: Silent alpha(2C)-adrenergic receptors enable cold-induced vasoconstriction in cutaneous arteries. Am J Physiol Heart Circ Physiol 2000, 278:H1075\u2013H1083.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"16_CR50","doi-asserted-by":"crossref","first-page":"3994","DOI":"10.1002\/art.20665","volume":"50","author":"R.A. Wise","year":"2004","unstructured":"Wise RA, Wigley FM, White B, et al.: Efficacy and tolerability of a selective alpha(2C)-adrenergic receptor blocker in recovery from cold-induced vasospasm in scleroderma patients. A single-center, double-blind, placebo-controlled, randomized crossover study. Arthritis Rheum 2004, 50:3994\u20134001.","journal-title":"Arthritis Rheum"}],"container-title":["Current Treatment Options in Cardiovascular Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11936-008-0016-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11936-008-0016-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11936-008-0016-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T00:56:32Z","timestamp":1559436992000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11936-008-0016-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,3,29]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,4]]}},"alternative-id":["16"],"URL":"https:\/\/doi.org\/10.1007\/s11936-008-0016-y","relation":{},"ISSN":["1092-8464","1534-3189"],"issn-type":[{"value":"1092-8464","type":"print"},{"value":"1534-3189","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,3,29]]}}}